These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 18628466

  • 1. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
    Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C.
    Clin Cancer Res; 2008 Jul 15; 14(14):4511-6. PubMed ID: 18628466
    [Abstract] [Full Text] [Related]

  • 2. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
    Bernard-Marty C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A.
    Clin Breast Cancer; 2002 Dec 15; 3(5):341-5. PubMed ID: 12533264
    [Abstract] [Full Text] [Related]

  • 3. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
    Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, Monden M, Noguchi S.
    Clin Cancer Res; 2003 Aug 01; 9(8):2992-7. PubMed ID: 12912947
    [Abstract] [Full Text] [Related]

  • 4. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
    Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Von Minckwitz G, Leroy JY, Durbecq V, Isola J, Aapro M, Piccart MJ, Larsimont D.
    Breast Cancer Res Treat; 2004 Aug 01; 86(3):197-206. PubMed ID: 15567936
    [Abstract] [Full Text] [Related]

  • 5. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller EL, Dumontet C.
    Clin Cancer Res; 2005 Aug 01; 11(15):5481-6. PubMed ID: 16061864
    [Abstract] [Full Text] [Related]

  • 6. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
    Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechère L, Reed JC.
    Clin Cancer Res; 2010 Aug 01; 16(15):3988-97. PubMed ID: 20576719
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
    Urano N, Fujiwara Y, Doki Y, Kim SJ, Miyoshi Y, Noguchi S, Miyata H, Takiguchi S, Yasuda T, Yano M, Monden M.
    Int J Oncol; 2006 Feb 01; 28(2):375-81. PubMed ID: 16391792
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
    Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA.
    Cancer; 2007 Sep 15; 110(6):1248-54. PubMed ID: 17674353
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA.
    Semin Oncol; 1999 Jun 15; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [Abstract] [Full Text] [Related]

  • 18. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
    Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D.
    Mol Cancer Ther; 2004 Oct 15; 3(10):1207-14. PubMed ID: 15486187
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer.
    Niu ZH, Wang Y, Chun B, Li CX, Wu L.
    Eur Rev Med Pharmacol Sci; 2013 May 15; 17(10):1337-44. PubMed ID: 23740447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.